(2S)-1-[(2S)-2-[(1-Ethoxycarbonyl-3-Phenyl-Propyl)Amino]Propanoyl]Pyrrolidine-2-Carboxylic Acid

What Drives Low-Dose Blend Uniformity Failure on High-Speed Presses?

In direct-compression tablet manufacturing for enalapril maleate 5 mg, 10 mg, and 20 mg dosage strengths, the micronized active pharmaceutical ingredient—typically exhibiting a particle size distribution with D90 below 20 µm—presents severe cohesive agglomeration tendencies when combined with coarse excipients such as microcrystalline cellulose (Avicel PH-102) and lactose monohydrate (Pharmatose 200M). Stratified sampling data from industrial-scale V-blenders (Patterson-Kelly, 1200 L working capacity, 12 rpm) reveal that after 25 minutes of blending without an intensifier bar, the relative standard deviation (RSD) of the active content across 10 sampling ports frequently exceeds 6.0%, which is non-conformant with the USP <905> uniformity of dosage units requirement mandating an acceptance value (AV) ≤15.0 for 10 tablets. The primary failure mode is not insufficient shear but electrostatic adhesion of the fine API particles to the blender shell and to the surfaces of larger excipient carriers, a phenomenon quantified by drop-tested surface-sampling recoveries as low as 88% of label claim in the first decile of the batch discharge. To mitigate this, formulators introduce colloidal silicon dioxide (Aerosil 200) at 0.5–1.0 wt% as a glidant pre-blended with the API in a high-shear co-mill (Quadro Comil, 457 µm rasp screen, 1500 rpm) prior to the main blending step, which reduces agglomerate cohesive energy by adsorbing surface moisture down to monolayer levels at water activity below 0.3. Even with this, tablet compression on a 45-station rotary press (Kikusui Aquarius, 70 rpm turret speed, 8–14 kN compression force) demands in-line near-infrared (NIR) blend uniformity monitoring at the feed frame to detect compositions drifting outside the 90.0–110.0% label claim window, as material segregation re-occurs when vibration-induced percolation of fines through the clearance volumes of the die table exceeds the critical amplitude of 0.3 mm at 60 Hz operation. Failure to control this results in superpotent tablets (individual content >115.0%) interdispersed with subpotent units (85.0%), a pattern flagged by out-of-specification dissolution at the Q=80% in 30 minutes condition of USP <711> using Apparatus 2 (paddle, 50 rpm, 900 mL pH 6.8 phosphate buffer) because poorly wetted agglomerates in superpotent zones undergo delayed disintegration.

Launching directly into the commercial manufacture of angiotensin-converting enzyme inhibitor intermediates, the preparation of the dipeptide free acid (2S)-1-[(2S)-2-[(1-ethoxycarbonyl-3-phenyl-propyl)amino]propanoyl]pyrrolidine-2-carboxylic acid as the penultimate precursor to enalapril maleate requires strictly controlled stereochemical integrity at both chiral centers. The N-alkylation of L-alanyl-L-proline dipeptide with ethyl 2-oxo-4-phenylbutyrate under catalytic hydrogenation over 5% Pt/C (0.5 MPa H₂, 50°C, ethanol/water 4:1 v/v) yields the crude ester with diastereomeric excess (de) typically exceeding 99.5% after recrystallization from acetone/water. Any residual (R,S)- or (S,R)-diastereomer exceeding 0.3% directly propagates into the final maleate salt as a specified impurity, detected by a validated chiral HPLC method (Chiralpak AD-H column, 250×4.6 mm, hexane/ethanol/trifluoroacetic acid 80:20:0.1 mobile phase, UV 215 nm) and limited per ICH Q3B(R2) reporting threshold of 0.05% for a maximum daily dose of 40 mg. Production-scale batches exceeding 50 kg cope with a reaction mass transfer barrier because the hydrogenation rate—pseudo-first-order with respect to dissolved H₂ concentration—drops precipitously if the agitator tip speed in a 2000 L glass-lined reactor falls below 2.5 m/s, creating stagnant zones where Schiff base intermediates hydrolyze back to the starting ketone, reducing overall yield below the economic threshold of 85%. The salt formation step with maleic acid (molar ratio 1.0:1.05, isopropanol, 40–45°C) introduces an additional risk: over-acidification below pH 3.0 catalyzes ethyl ester hydrolysis to enalaprilat at a rate exceeding 0.1% per hour at 45°C, so neutralization is terminated at a potentiometric endpoint of pH 3.8±0.1, and the crystallizing slurry is immediately cooled to 0–5°C at a controlled ramp of 0.2°C/min to avoid encrustation on cooling coils while limiting residual enalaprilat to ≤0.5% as per USP monograph.

Fixed-Dose Enalapril/Hydrochlorothiazide and the Segregation Boundary in Monolithic Tablets

Combining enalapril maleate (10 mg) with hydrochlorothiazide (25 mg) in a single-layer tablet amplifies blend uniformity and dissolution interference risks because the two actives differ in particle size by nearly an order of magnitude—enalapril maleate D90 ≈20 µm, hydrochlorothiazide D90 ≈150 µm after jet-milling—and exhibit opposing solubility-pH profiles. Wet granulation using an aqueous polyvinylpyrrolidone (Kollidon 30) binder solution at 5% w/w concentration is preferred over direct compression: the hydrochlorothiazide is first granulated with lactose and pre-gelatinized starch in a high-shear mixer (GEA PMA 600, 300 L bowl, chopper at 1500 rpm, main impeller at 120 rpm) to form granules of mass median diameter 180–250 µm, and the enalapril maleate premix with microcrystalline cellulose is added extra-granularly to avoid exposure to the aqueous binder, which would induce partial dissolution and re-crystallization as amorphous domains with lowered stability. Drying is conducted in a fluid bed (Glatt WSG 120) with inlet air temperature limited to 50°C and endpoint loss-on-drying ≤2.0%; excursions above 55°C for more than 15 minutes trigger enalapril diketopiperazine formation at a rate of 0.02% per minute, at which point the total impurity burden approaches the ICH Q3B qualification threshold of 0.2%. The segregation boundary manifests downstream when the extra-granular enalapril fines migrate through interstitial voids in the granule bed during hopper discharge into the rotary press feed frame—a process quantified by tapped density differentials: the granule fraction has a Carr’s compressibility index of 12% while the enalapril-enriched fines register 32%. Tablet press force-distance profiles (recorded on a Korsch XL 400, sampling at 2 kHz) show compression force fluctuations exceeding ±1.5 kN when the blend ratio drifts, yielding weight variation RSD >3.0% versus the 1.5% target. An in-line Raman probe focused on the ejection cam of the rotary press detects the changing enalapril-to-HCTZ ratio by tracking the intensity of the sulfonamide symmetric stretch at 1155 cm⁻¹ relative to the ester carbonyl at 1740 cm⁻¹; when the ratio deviates by more than ±5% of the nominal, the press alarm triggers automatic rejection of 30 subsequent tablets to prevent out-of-specification batch release.

The above monograph alignment dictates that enalapril maleate intended for multinational finished dosage form filing must achieve total impurities ≤0.8% at release to satisfy Japanese and European markets, which effectively tightens the drying and storage thermal budget below the 0.3% diketopiperazine ceiling even though USP allows 0.3% for that specific impurity. Manufacturing under a harmonized ICH Q7 GMP framework requires that batch records document the maximum temperature experienced by the enalapril maleate lot from crystallization through final blending and that excursions be investigated as deviations. The combination product additionally triggers a bioequivalence requirement under 21 CFR 320.24 if the formulation is submitted as an ANDA referencing a listed drug, where dissolution similarity (f2 ≥ 50) in pH 1.2, pH 4.5, and pH 6.8 media must be demonstrated for both enalapril and HCTZ components, each analyzed via a specific stability-indicating LC-UV method separately validated per ICH Q2(R1).

Veterinary Oral Solutions – pH Buffering and Palatability Masking

Formulating the dipeptide acid into liquid veterinary products (commonly enalapril maleate 1 mg/mL or 2.5 mg/mL oral solution for dogs) imposes a solubility–stability conflict: the maleate salt is freely soluble in water (> 150 mg/mL at 25°C), but its hydrolytic degradation to enalaprilat follows a pH-rate profile with minimal breakdown at pH 3.0–4.5 and a rapid acceleration above pH 5.5 (k ≈ 1.2×10⁻³ day⁻¹ at 25°C at pH 6.0 versus 3.5×10⁻⁵ day⁻¹ at pH 4.0). Commercial solutions are therefore buffered to pH 4.0–4.3 using 10 mM citrate or phosphate-citrate buffer, with sodium benzoate (0.1%) added as preservative effective only below pH 4.5 where it remains predominantly as undissociated benzoic acid (pKa 4.2). Palatability for canine patients is achieved through the addition of artificial beef flavor and sucralose (0.05–0.1%), but the challenge is that sucralose degrades with a concurrent pH drop of 0.3–0.5 units over 12 months at 30°C/65% RH, an effect that can push the solution into the zone where enalapril precipitation occurs if the pH falls below 3.5 due to suppression of the carboxylic group ionization. Manufacturing-scale compounding ( 500 L stainless steel tank, bottom-mounted magnetic drive agitator, 200 rpm) demands inert gas blanketing (nitrogen, 0.2 bar overpressure) because enalapril maleate undergoes photo-oxidative degradation at the ethoxycarbonyl moiety under ambient fluorescent light (exposed intensity > 500 lux), forming the N-oxide derivative detected at RRT 1.45 in a Ph.Eur. impurity method. The product is filled into amber PET bottles with child-resistant closures (compliant with 16 CFR 1700.20) and labeled with a beyond-use date not exceeding 24 months when stored below 25°C. Manufacturers targeting EU markets must also satisfy VICH GL18 residual solvent limits, ensuring that any isopropanol from the salt formation step is reduced to ≤ 5000 ppm (Class 3 solvent) through vacuum distillation at ≤ 40°C prior to aqueous dissolution.

Chiral Intermediate Stability During Long-Term Storage in Bulk Containers

Warehousing bulk enalapril maleate technical-grade material in fiber drums with LDPE liners at ambient climatic conditions (Class 25°C/60% RH) for periods exceeding 12 months triggers a cascade of physical and chemical degradation pathways that are often underestimated in supply-chain risk assessments. The compound is moderately hygroscopic; moisture uptake from the headspace at 60% RH increases water content from 0.15% to 0.9% within 30 days of liner breach, crossing the threshold where unfrozen water mobility facilitates the intramolecular cyclization to diketopiperazine with an activation energy of approximately 85 kJ/mol derived from Arrhenius studies at 40–70°C. Simultaneously, the maleate counterion can undergo isomerization to fumaric acid under UV exposure (wavelengths 300–400 nm), detectable as a white needle crystal formation on the inner drum walls, which not only depletes the stoichiometric maleate content needed for consistent salt-to-free-acid dissolution behavior but also introduces fumaric acid as a process-related impurity that must be quantified and reported if above 0.10% per ICH Q3A. A proactive measure adopted by traders and distributors for shipments to Zone IVb countries is the use of aluminum-laminate barrier bags with heat-sealed closures under nitrogen atmosphere (residual oxygen 0.5%), achieving a water vapor transmission rate below 0.05 g/m²/day at 38°C/90% RH and limiting diketopiperazine accumulation to 0.05% over 24 months when supplemented with a silica gel desiccant (min. 200 g per 25 kg drum). The retest date is assigned by applying a zero-order kinetic model: once the sum of diketopiperazine and enalaprilat exceeds 0.6%, the lot is downgraded to technical grade for non-pharmaceutical research use only. No re-milling or sieving operation can reverse the diastereomeric enrichment that occurs if partial epimerization at the alanyl α-carbon happens in aqueous-organic biphasic storage conditions; thus, high-performance liquid chromatography chiral purity certificates (limit: SSS-RRS diastereomer ≤0.3%) from the original manufacturer become mandatory for each container released after transoceanic transit.